Teva Pharmaceutical Industries Limited (TEVA) Downgraded by BidaskClub

BidaskClub downgraded shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) from a sell rating to a strong sell rating in a research note published on Friday morning.

Other equities analysts also recently issued research reports about the company. Vetr downgraded Teva Pharmaceutical Industries Limited from a hold rating to a sell rating and set a $31.05 target price on the stock. in a research report on Thursday, June 22nd. Cantor Fitzgerald set a $31.00 target price on Teva Pharmaceutical Industries Limited and gave the company a hold rating in a research report on Thursday, June 22nd. Citigroup Inc. cut Teva Pharmaceutical Industries Limited from a buy rating to a neutral rating and cut their price target for the company from $32.00 to $19.00 in a report on Wednesday, August 16th. Maxim Group reaffirmed a hold rating and issued a $35.00 price target on shares of Teva Pharmaceutical Industries Limited in a report on Thursday, July 13th. Finally, Credit Suisse Group reaffirmed an outperform rating and issued a $39.00 price target on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, August 9th. Five investment analysts have rated the stock with a sell rating, eighteen have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average price target of $27.63.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 14.71 on Friday. The firm has a 50-day moving average price of $16.73 and a 200-day moving average price of $26.05. The company’s market cap is $14.95 billion. Teva Pharmaceutical Industries Limited has a 1-year low of $14.30 and a 1-year high of $44.42.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the consensus estimate of $1.06 by ($0.07). The firm had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business’s revenue was up 12.9% compared to the same quarter last year. During the same quarter last year, the business earned $1.25 EPS. On average, equities analysts expect that Teva Pharmaceutical Industries Limited will post $4.24 EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was first published by BBNS and is the property of of BBNS. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/teva-pharmaceutical-industries-limited-teva-downgraded-by-bidaskclub/1715495.html.

A number of large investors have recently added to or reduced their stakes in the stock. Capital Research Global Investors boosted its holdings in Teva Pharmaceutical Industries Limited by 13.8% in the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after purchasing an additional 9,260,426 shares during the period. Franklin Resources Inc. boosted its holdings in Teva Pharmaceutical Industries Limited by 11.1% in the second quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock valued at $2,218,958,000 after purchasing an additional 6,685,844 shares during the period. FMR LLC boosted its holdings in Teva Pharmaceutical Industries Limited by 16.7% in the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after purchasing an additional 6,115,853 shares during the period. Northern Cross LLC boosted its holdings in Teva Pharmaceutical Industries Limited by 14.0% in the second quarter. Northern Cross LLC now owns 17,795,579 shares of the company’s stock valued at $591,169,000 after purchasing an additional 2,184,172 shares during the period. Finally, Nordea Investment Management AB boosted its holdings in Teva Pharmaceutical Industries Limited by 2.5% in the second quarter. Nordea Investment Management AB now owns 12,884,810 shares of the company’s stock valued at $428,033,000 after purchasing an additional 311,894 shares during the period. Hedge funds and other institutional investors own 56.76% of the company’s stock.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with our FREE daily email newsletter.

 


Latest News

Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Yankees to Send Masahiro Tanaka Against Astros in Game 1
Red Sox Waste Little Time in Firing John Farrell
Red Sox Waste Little Time in Firing John Farrell
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Washington Nationals Sans Strasburg for Game 4 at Wrigley
Red Sox Beat Houston Sunday to Avoid Elimination
Red Sox Beat Houston Sunday to Avoid Elimination


Leave a Reply

 
© 2006-2017 BBNS.